Navidea Biopharmaceuticals, Inc. announced that the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the NYSE American LLC upheld the NYSE Regulation staff’s previously announced determination to initiate delisting proceedings with respect to the Company’s common stock.
